Successful treatment in a child with enthesitis-related arthritis involving the sternoclavicular joint: a case report

Po-Yu Huang 1†, Ling-Sai Chang 2†, Mindy Ming-Huey Guo 2 and Ho-Chang Kuo 2

Abstract

Background: Although the sternoclavicular joint (SCJ) may be involved in ankylosing spondylitis, rheumatic arthritis, and Behçet’s disease and participates in the systemic inflammatory process of arthritis, it is often neglected during routine rheumatologic clinical examinations. To the best of our knowledge, this is the first study to report etanercept treatment in juvenile idiopathic arthritis (JIA) with SCJ involvement.

Case presentation: In this study, we describe an unusual case of a child with juvenile idiopathic arthritis with an initial presentation of sternoclavicular mass. The patient (age, 14 years 10 months) presented with an insidious onset atraumatic swelling of the left SCJ and complained of right hip and bilateral ankle tenderness without an apparent cause. Initial ultrasonography indicated a heterogeneous mass in the left SCJ, while computed tomography identified mild swelling of the left SCJ with a thickened synovial lining, mild bone erosion, and some turbid fluid. The patient ultimately underwent left SCJ arthrotomy, during which tapping of the SCJ revealed 2 cc of yellowish fluid, inflammation and necrosis of tissues within the SCJ. A clear yellow joint fluid was aspirated, and testing revealed a negative culture result. The patient was diagnosed with JIA.

Conclusions: JIA with SCJ involvement is an uncommon presentation in adolescents. Etanercept may be a beneficial treatment for SCJ involvement in patients with JIA. The upper limbs showed no signs of limited range of motion during the follow-up period. Further studies are warranted to elucidate the efficacy of etanercept in JIA with sternoclavicular joint involvement.

Keywords: Etanercept, Juvenile idiopathic arthritis, Sternoclavicular joint, Ultrasonography

Background

Juvenile idiopathic arthritis (JIA) is a heterogeneous group of disorders. Enthesitis-related arthritis (ERA) is a category of JIA, defined by the International League of Associations for Rheumatology (ILAR) [1]. This form of JIA is characterized by enthesitis and hip arthritis [2]. Sacroilitis and low back pain (LBP) develop in the later stages of the disease. ERA demonstrates vast geographical differences, with a remarkably high prevalence (37.4%) in the Taiwanese population [3]. The etiology of JIA is hypothesized that a susceptible individual with distinct genetic background could develop an uncontrolled immune response towards a self-antigen on exposure to an uncertain stimulation [4]. The expansion of pathogenetic studies has increased our understanding of the immunopathogenesis. Depression of CD8+ suppressor T lymphocyte functions is one of the important mechanisms underlying clinically active JIA [5–7].

Sternoclavicular joint (SCJ) lesions are rare and commonly ignored as they are often painless or considered benign. Nevertheless, SCJ lesions have a number of diagnostic and therapeutic standards. Possible differential diagnoses of SCJ can include infective, neoplastic, rheumatological, degenerative, and idiopathic conditions [8]. The differential diagnosis of unilateral SCJ arthritis

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
is sometimes challenging as it can include infective and inflammatory pathologies like sternal osteomyelitis, septic arthritis, and systemic arthritis of SCJ. A previous report described synovial cysts involving bilateral SCJs in a poly-articular JIA case [9]. Synovial proliferation and accumulation of synovial fluid may contribute to the development of a synovial joint cyst. In systemic arthritis, osteoarthritis is the most frequent cause of pain and swelling of the SCJ [8]. A strong association has been found between seronegative spondyloarthropathy and SCJ involvement [10]. Traditionally, spondyloarthritis has been differently classified in adults and children. Using the ILAR system for JIA, most childhood spondyloarthritis is classified as enthesitis-related arthritis [11].

A retrospective study analyzing Brazilian patients diagnosed with ankylosing spondylitis identified sternoclavicular involvement in 14.3% [12]. Juvenile spondyloarthritis has been associated with articular involvement of the lower limbs, but not sternoclavicular involvement. However, the SCJs may be one of the first joints to become involved in juvenile ankylosing spondylitis [13]. A previous case-control study reported 14 patients with juvenile spondyloarthritis accompanied with costosternal pain, six of which had reduced chest expansion [14]. Using ultrasound, another study detected greater synovitis and erosions of the involved SCJ in patients with rheumatoid arthritis [15]. Behçet’s disease may also involve the SCJs. In one study, two patients presented with destructive arthritis that involved the SCJ [16].

The following study details the case of a 14-year-old boy with a 3-month history of pain and swelling of the left SCJ. This report aims to present our experience with SCJ management in JIA.

**Case presentation**

A 14-year-10-month-old Han Taiwanese boy was presented to the pediatric out-patient clinic with a 3-month history of swelling of the left clavicle. His family history included his father’s ankylosing spondylitis and his mother’s uveitis. Physical examination revealed mild tenderness. An erythematous immobile firm mass measuring approximately 2 × 2.5 cm was found overlying the left proximal clavicle, immediately lateral to the SCJ. Furthermore, he expressed pain when the clinician pressed down on his right hip and bilateral ankles. We did not perform modified Schober test in our patient because LBP was not obvious and he was a suspicious case of JIA.

The patient had right hip arthritis and bilateral Achilles enthesitis. White blood cells count was $7.8 \times 10^3 /\mu l$, with 57% neutrophils and 32% lymphocytes (normal 3.9–10.6 × 10^3 /μl; neutrophils 42–74%; lymphocytes 20–56%). Biological inflammatory syndrome was observed with elevated erythrocyte sedimentation rate (33 mm/hr.; normal < 17 mm/hr) and C-reactive protein (22.6 mg/l; normal < 5 mg/L). Human leucocyte antigen (HLA) typing was positive for B27. Meanwhile, uric acid, rheumatoid factor, complements C3 and C4, anti-nuclear antibody, and anti-double-strand DNA were all normal. Furthermore, his renal and liver function, urine analysis, and muscle enzyme tests results were all normal.

The patient was initially treated empirically with oral augmentin (amoxicillin trihydrate + clavulanate potassium) and cefixime for 1 week, but did not respond favorably to the antibacterial treatment. We then treated the patient with naproxen (500 mg/day), a non-steroidal anti-inflammatory agent, and followed up. He claimed to have no history of trauma, fever, weight loss, loss of

**Fig. 1** Ultrasonography of the left sternoclavicular joint shows a heterogeneous hypoechoic mass in a 14-year-10-month-old male patient with juvenile idiopathic arthritis
appetite, or intravenous drug abuse. We observed no skin lesions, such as acne or pustulosis palmaris et plantaris. Ultrasonography examination revealed a heterogeneous hypoechoic mass in the left SCJ (2 x 2.5 cm; Fig. 1), and he was hospitalized to our pediatric ward. A computed tomography (CT) scan of the chest further indicated a turbid collection at the left SCJ (Fig. 2). Bone window testing demonstrated irregular bone surfaces on the SCJ due to erosion, thus suggesting arthritis. Bone scintigraphy (MDP Tc-99 m) showed a focal area of increased uptake in the trochanteric region of the right proximal femur (Fig. 3).

We performed a left SCJ arthrotomy on the patient, in which the clavicular head was excised and the left SCJ was debrided. Due to suspicion of malignant infiltration, we performed a histopathological examination, but no malignant cells were observed. A histologic examination of the tissue exposed acute and chronic inflammatory cell infiltration. Aspirated joint fluid cultures were negative; therefore, diagnosis of infection could be excluded.

In view of the historical facts and clinico-radiological correlation, including CT findings, we made a working diagnosis of JIA of the medial end of the left clavicle and initiated JIA therapy. The onset of arthritis and enthesitis after 6 years of age in a boy with HLA-B27 and a family history allowed him to meet the strict diagnostic criteria of the JIA subtype enthesitis-related arthritis. Given that SCJ disorders are rare, there is a probability that many clinicians do not have substantial training or experience injecting the SCJ with corticosteroids [17]. This lack of experience, combined with a complex and frequently distorted SCJ anatomy, may result in poor injection accuracy. After surgical debridement, we prescribed a naproxen, sulfasalazine 1000 mg/day (4 months before prednisolone), and prednisolone 0.6 mg/kg/day combination for 4 weeks, followed by naproxen + oral methotrexate (MTX) 10 mg/m²/week + prednisolone for the next 3.5 months. Due to persistent high disease activity under sulfasalazine, an alternate immunomodulator therapy MTX was selected. Etanercept has been indicated in the treatment of refractory JIA [18]. He achieved full remission from the JIA with etanercept 25 mg twice a week within 4 weeks (Fig. 4), and tolerated etanercept with good adherence. The patient reported complete cessation of pain and no longer needed analgesics, MTX, or prednisolone after 3 months. The aim of our treatment was to achieve maximum effectiveness and reduce the dosage of concomitant therapy because concomitant therapy substantially elevates the risk of side effects. A prospective study also revealed the effectiveness of etanercept therapy [19]. Furthermore, 38.3% of patients with JIA treated with etanercept in combination with any medication could completely discontinue these concomitant drugs. Our patient continued the etanercept treatment 25 mg twice a week for at least 2 years to maintain a stable condition without any relapse during the outpatient follow-up. We repeated the ultrasound of the left clavicle, which revealed complete healing of the initial findings after 13 months of etanercept treatment.

Discussion and conclusions
In this case report, we described a 14-year-10-month-old male patient with JIA who received biologic treatments. This case suggests a possible relationship between JIA and SCJ involvement.

Anti-tumor necrosis factor is an effective treatment for patients with JIA resistant to non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). There is evidence to
support that Etanercept, one of the TNF-α inhibitors, improves JIA-associated symptoms and prevents flare [20, 21]. Additionally, Etanercept demonstrated its effectiveness in ERA [22, 23]. A meta-analysis concluded that etanercept is as effective as abatacept, adalimumab, and tocilizumab [24]. However, etanercept was not successfully discontinued in patients without JIA recurrence [25]. Patients treated with etanercept have a lower chance of infection compared to patients treated with infliximab [26]. Taiwanese children with JIA who received TNF inhibitors were not at higher risk of tuberculosis [27]. The reported adverse events of etanercept were hypersensitive joint reaction, skin rash, upper respiratory tract infection, monoarticular septic arthritis, headache, and fatigue [28, 29]. Currently, DMARDs and corticosteroids are largely used as bridge or adjunctive therapies [30]. The ERA category usually affects >6-year-old boys and presents with enthesitis. The presence

Fig. 3 A bone scan reveals increased uptake of the right proximal femur at the trochanteric region, reflecting the patient with juvenile idiopathic arthritis in whom the bones were affected.

Fig. 4 The erythrocyte sedimentation rate (ESR) and 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) in a child with juvenile idiopathic arthritis during the observation period. The joint pain and swelling completely resolved in the second month of treatment with etanercept, and laboratory values improved in accordance with the clinical course of the patient.
of hip or ankle arthritis and a family history of spondyloarthropathy or polyarticular joint involvement at onset are correlated with poor prognosis [31]. Current guidelines support the use of sulfasalazine to treat ERA [15].

The most important differential diagnosis is chronic non-bacterial osteitis (CNO). Synovitis, acne, pustulosis, hyperostosis, osteitis syndrome (SAPHO) describes the same disease entity. The bone scintigraphy result indicates a lesion in the femur. This makes CNO a probable diagnosis for this case. Magnetic resonance imaging figures were inconclusive, but the involvement of SCJ may be due to primary involvement of proximal end of clavicle with CNO. Therapeutic strategies for CNO include non-steroidal anti-inflammatory drugs (NSAIDs), which are often highly effective [32]. Etanercept could be effective in CNO. However, our patient responded poorly to NSAIDs. Furthermore, the strong family history with positive HLA-B27 suggested a case of ERA.

This is the first report of successful use of etanercept in the treatment of JIA with SCJ involvement. In general, physicians should pay attention to SCJ involvement in patients with JIA. Future prospective studies are warranted to testify whether adding etanercept to DMARDs can rescue SCJ involvement in JIA.

Abbreviations

Anti-TNF: Anti-tumor necrosis factor; CNO: Chronic non-bacterial osteitis; CT: Computed tomography; DMARDs: Disease-modifying anti-rheumatic drugs; ERA: Enthesitis-related arthritis; HLA: Human leucocyte antigen; ILAR: International League of Associations for Rheumatology; JIA: Juvenile idiopathic arthritis; LB: Low back pain; MTX: Methotrexate; NSAIDs: Non-steroidal anti-inflammatory drugs; SCJ: Sternoclavicular joint.

Acknowledgements

The authors would like to express their gratitude to all hospital personnel involved in this study.

Authors’ contributions

P-YH, LS-L, MM-HG, and H-CK drafted and approved the final manuscript. L-SC revised it for intellectual content and approved the final manuscript.

Funding

This work was supported by a grant from the Kaohsiung Chang Gung Memorial Hospital (CMRPG8H1161). However, these institutions had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials

Please contact the authors for all data requests.

Ethics approval and consent to participate

Ethics committee approval was obtained from Kaohsiung Chang Gung Memorial Hospital’s ethics committee (IRB 20190050280).

Consent for publication

Written informed consent was obtained by the parents of the patient for the publication of this case report and any included images.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Traditional Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung 83301, Taiwan. 2Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, #123 Da-Pei Road, Niaosong District, Kaohsiung 83301, Taiwan.

Received: 2 April 2019 Accepted: 2 October 2019
Published online: 23 October 2019

References

1. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.

2. Goïnard M, Breton S, Chevallier F, Duong NP, Uettwiller F, Melki J, et al. Clinical features of children with enthesitis-related juvenile idiopathic arthritis / juvenile spondyloarthropathies followed in a French tertiary care pediatric rheumatology Centre. Pediatr Rheumatol Online J. 2018;16:21.

3. Shen CC, Yeh KW, Ou LS, Yao TC, Chen LC, Huang JL. Clinical features of children with juvenile idiopathic arthritis using the ILAR classification criteria: a community-based cohort study in Taiwan. J Microbiol Immunol Infect. 2017;50:1–11.

4. Tosti A. Hair disorders. 2013:99–106.

5. Filaci G, Rizzi M, Setti M, Fenoglio D, Favega M, Basso M, et al. Non-antigen-specific CD8(+ T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci. 2005;1050:115–23.

6. Silverman ED, Somma C, Khan MM, Melmon KL, Engleman EG. Abnormal T suppressor cell function in juvenile rheumatoid arthritis. Arthritis Rheum. 1996;33:205–11.

7. Ichikawa M, Yanagisawa M, Kawai H, Kaminodai M, Komiyama A, Akabane T. Spontaneous improvement of juvenile rheumatoid arthritis after T lymphocytosis with suppressor phenotype and function. J Clin Lab Immunol. 1998;27:197–201.

8. Robinson CM, Jenkins PJ, Markham PE, Beggs I. Disorders of the sternoclavicular joint. J Bone Joint Surg Br. 2008;90:865–96.

9. Joseph F, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017;29:523–9.

10. Filaci G, Rizzi M, Setti M, Fenoglio D, Favega M, Basso M, et al. Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. Ann N Y Acad Sci. 2005;1050:115–23.

11. Colbert RA. Classification of juvenile spondyloarthritides: enthesitis-related arthritis and beyond. Nat Rev Rheumatol. 2010;6:477–85.

12. Sampaio-Barros PD, Bertolo MB, Kraemer MH, Neto JF, Samara AM. Primary ankylosing spondylitis: patterns of disease in a Brazilian population of 147 patients. J Rheumatol. 2001;28:560–5.

13. Matuszewska G, Zaniewicz-Kaniewska K, Wlodkowica-Korytkowska M, Smorawińska P, Saied F, Kunzis W, et al. Radiological imaging in pediatric rheumatic diseases. Pol J Radiol. 2014;79:1–8.

14. Burgos-Vargas R, Vazquez-Mellado J, Cassis N, Duarte C, Casarin J, Cifuentes M, et al. Genuine ankylosing spondylitis in children: a case-control study of patients with early definite disease according to adult onset criteria. J Rheumatol. 1996;23:2140–7.

15. Rodriguez-Henriquez P, Solano C, Pena A, Leon-Hernandez S, Hernandez-Diaz C, Gutierrez M, et al. Sternoclavicular joint involvement in rheumatoid arthritis: clinical and ultrasound findings of a neglected joint. Arthritis Care Res (Hoboken). 2013;65:1177–82.

16. Frikha F, Marzouk S, Kaddour N, Frigui M, Bahloul Z. Destructive arthritis in Behcet’s disease: a report of eight cases and literature review. Int J Rheum Dis. 2009;12:250–5.

17. Poucho AM, Sellon JL, Smith J. Sonographically guided sternoclavicular joint injection: description of technique and validation. J Ultrasound Med. 2015;34:325–31.

18. Kuo HC, Yu HR, Wu CC, Chang LS, Yang KD. Etanercept treatment for children with refractory juvenile idiopathic arthritis. J Microbiol Immunol Infect. 2011;44:52–6.

19. Alesheva E, Dvoryakovskykaya T, Denisova R, Slepsova T, Isaeva K, Chomahiedze A, et al. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate. Pediatr Neonatol. 2019;60(5):459–55. https://doi.org/10.1016/j.pedneo.2019.02.003.

20. Kemper AR, Van Mater HA, Coeytaux RR, Williams JW Jr, Sanders GD. Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis. BMC Pediatr. 2012;12:1471–2431.
21. Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342:763–9.
22. Murdaca G, Negrini S, Magnani O, Penza E, Pellecchio M, Gulli R, et al. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis. Mod Rheumatol. 2018;28:417–31.
23. Foeldvari I, Constantin T, Vojinovic J, Horneff G, Chasnyk V, Dehoorne J, et al. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial. Arthritis Res Ther. 2019;21:125.
24. Amriloyo G, Tarp S, Foeldvari I, Cohen N, Pope TD, Woo JM, et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016;46:312–8.
25. Davies R, Gaynor D, Hynch KL, Pain CE. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review. Semin Arthritis Rheum. 2017;46:584–93.
26. Murdaca G, Negrini S, Pellecchio M, Greco M, Schiavi C, Giusti F, et al. Update upon the infection risk in patients receiving TNF alpha inhibitors. Expert Opin Drug Saf. 2019;18:219–29.
27. Hsin YC, Zhuang LZ, Yeh KW, Chang CW, Horng JT, Huang JL. Risk of tuberculosis in children with juvenile idiopathic arthritis: a nationwide population-based study in Taiwan. PLoS One. 2015;10:e0128768.
28. Lin KC, Liang CD, Yang KD, Yu HR, Kuo HC. Monoarticular septic arthritis in a patient with juvenile rheumatoid arthritis under etanercept treatment. Rheumatol Int. 2012;32:1383–5.
29. Guo WW, Yang KD, Yu HR, Kuo HC. Hypersensitive joint reaction after etanercept treatment in a patient with juvenile rheumatoid arthritis. The J Rheumatol. 2011;38:577–9.
30. Stoll ML, Cron RQ. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:1546–0096.
31. Aggarwal A, Misra DP. Enthesitis-related arthritis. Clin Rheumatol. 2015;34:1899–46.
32. Wintrich S, Horneff G. Characteristics and outcomes of chronic non-bacterial osteitis in children. Eur J Rheumatol. 2015;2:139–42.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.